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Abstract
Light-induced retinal degeneration is characterized by photoreceptor cell death. Many studies showed that photoreceptor demise is caspase-
independent. In our laboratory we showed that leucocyte elastase inhibitor/LEI-derived DNase II (LEI/L-DNase II), a caspase-independent apop-
totic pathway, is responsible for photoreceptor death. In this work, we investigated the activation of a pro-survival kinase, the protein kinase C
(PKC) zeta. We show that light exposure induced PKC zeta activation. PKC zeta interacts with LEI/L-DNase II and controls its DNase activity by
impairing its nuclear translocation. These results highlight the role of PKC zeta in retinal physiology and show that this kinase can control
caspase-independent pathways.
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Introduction
Genetic and oxidative stresses may damage the retina leading to
vision loss and, in dramatic cases, to blindness. Environmental fac-
tors such cigarette smoke, exposure to harmful substances and even
to intense light, are important in the progression of many retinopa-
thies [1]. There are good evidence supporting the fact that the light is
a factor producing retinal damages depending on radiation intensity
and on time of exposure [2, 3]. Many models have been developed to
study and evaluate the light toxicity (or phototoxicity, defined as the
thermal, chemical, or mechanical damage to the retina resulting of an
exposure to visible or ultraviolet light) on the retina and to elucidate
the mechanisms of oxidative stress-induced death of photoreceptors.
These models allowed a better understanding and identification of the
molecular process involved in degenerative retinal damages observed
in various retinopathies, because they present a synchronized death
of photoreceptors. Light-induced retinal degeneration (LIRD) has
been largely used to identify apoptosis as a mechanism of photore-
ceptors cell death [4]. In models of retinal degeneration, where weak
intensity of light and long-term exposure were used, the classical ef-
fectors of apoptosis are not activated [5–8], instead, a caspase-inde-
pendent pathway, the leucocyte elastase inhibitor (LEI)/L-DNase II
mediates photoreceptor demise [9, 10].
Leucocyte elastase inhibitor is an ubiquitous protease inhibitor of
the serpin family (serine protease inhibitor) [11]. It is a cytoplasmic
protein bearing an antiprotease activity. After cleavage by its cognate
protease LEI undergoes a conformational change that allows the
exposure of both an endonuclease active site and a nuclear localiza-
tion signal (NLS) [12, 13]. In this way LEI is transformed into
L-DNase II (LEI-derived DNase II) which is translocated to the
nucleus, where it cleaves DNA generating oligonucleosome fragments
bearing 30P ends [14]. We have previously shown that LEI/L-DNase II
has opposite activities regarding apoptosis: in its native state, LEI has
an anti-apoptotic function by preventing of proteolysis [15, 16],
whereas in its cleaved form it is pro-apoptotic by degrading genomic
DNA [15, 17].
Atypical protein kinase C (PKC) zeta is a serine threonin kinase
involved in cell protection against various stresses [18]. Our labora-
tory has shown that this kinase is activated in the retina following
intravitreal administration of tumour necrosis factor (TNF) [19] and
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that is cytoprotective in endotoxin-induced uveitis (EIU) [20]. As
many PKCs, it is a cytoplasmic protein which is translocated to the
plasma membrane or to the nucleus upon activation [21, 22]. This
activation can be modulated by its pseudo-substrate domain [23] or
by endogenous inhibitors such as prostate apoptosis response 4
(PAR4) that hides the catalytic domain of the kinase [24]. It has been
shown that following stress, activated PKC zeta phosphorylates Ikap-
pa kinase B, which leads, to the release of Nuclear Factor Kappa B
(NFkB) and its nuclear translocation. NFkB promotes the transcription
of anti-apoptotic genes such as Bcl-2, inhibitor of apoptosis protein,
TNF receptor-associated factors [25]. So that, activation of PKC zeta
and NFkB pathways act as inhibitory mechanisms of cell death in
stress response.
In this study, we show that PKC zeta is activated in LIRD. We
investigated if this activation is inhibiting the L-DNase II pathway for-
merly involved in this retinal degeneration.
Materials and methods
Retinal light damage in rats
Six to eight-week-old Fischer male rats were exposed to a constant light
and sacrificed as described before [9].
Intravitreal injection of PKC zeta inhibitor
The rats were anaesthetized by an intramuscular injection of xylazin (Rom-
pon; Bayer Pharma, Puteaux, France) at 10 mg/kg and ketamine (Keta-
mine Virbac 500; Vibrac France, Carros, France) at 40 mg/kg. A local
anaesthesia is performed by an instillation of oxybuprocaine (Cebesine;
Laboratoire Chauvin (Bausch and Lomb) Montpellier, France). The intravi-
treal injection of PKC zeta inhibitor is carried out under a surgical micro-
scope using a 30 G needle mounted on an insulin syringe (BD Micro-Fine,
Becton Dickinson S.A., Le Pont de Claix, France). PKC zeta inhibitor is
injected at a concentration of 6 lg per eye in a volume of 10 ll.
Protein extraction from illuminated retina
After defrosting, the retinas were homogenized in 20% weight-volume
of the M-PER extraction reagent (Thermo Scientific 78503, Illkirch,
France), using a pellet pestle motor homogenizer (KONTES) on ice. The
homogenate was then incubated on ice for 15 min. and then centrifuged
(15,000 9 g, 4°C) for 15 min. Supernatant was recovered for Western
blot analysis.
Preparation of cryosections
Enucleated eyes were embedded in optimal cutting-temperature medium
(Tissue Tek compound Sakura) cooled with liquid nitrogen. Cryosec-
tions of 10 lm were prepared by using a cryostat (Leica CM 3050S,
Nanterre, France) and stored at 20°C until immunohistochemical
analysis.
Cell lines and culture conditions
Baby hamster kidney (BHK) and HeLa cells (S3 clone) were cultured as
described before [26].
Cell death induction
HeLa cells were seeded at a density of 20,000 cells/cm2, maintained in cul-
ture for 2 days and then treated for 7 hrs with TNFa at 50 ng/ml (Gibco,
Life Technologies, Saint Aubin, France) and 10 lg/ml of cycloheximide
(CHX) (Sigma-Aldrich, Saint-Quentin Fallavier, France). Baby hamster kid-
ney cells were treated with 5-(N,N-hexamethylene) amiloride (HMA; stock
solution: 40 mM in DMSO, A9561; Sigma-Aldrich) at 40 lM for 18 hrs.
Pull-down assay
Recombinant proteins (wild-type LEI and calmodulin) were produced as
before [26]. Samples were dosed and resolved by SDS-PAGE and
immunoblotted for PKC zeta (C20, sc-216; Santa Cruz Biotechnology, Clin-
isciences, Nanterre, France). Calmodulin was used as a negative control
and a crude extract of HeLa cells was used as a positive control.
Co-immunoprecipitation
Co-immunoprecipitation was performed with the ProFoundTM Mammalian
Co-Immunoprecipitation Kit (Pierce, Thermo Fischer Scientific, Courta-
boeuf, France) as before [26]. The eluted material was then denatured
in Laemmli buffer and analysed by Western blot with LEI or PKC zeta
antibody. Column charged without IgG was used as a negative control.
Immunocytochemistry
HeLa cells were seeded in coverslips at the density of 5 9 104 cells/ml in
2 ml of complete medium using 12-multiwell plates. Forty-eight hours
after seeding they were treated with 50 ng/ml of TNFa plus 10 lg/ml of
CHX for 7 hrs. After treatment they were washed twice with PBS contain-
ing Ca2+ and Mg2+, fixed with 4% paraformaldehyde during 15 min. (all
steps were performed at room temperature) and then washed twice with
PBS. Permeabilization was performed with 0.3% Triton X100 in PBS for
20 min. Then, the cells were washed twice with PBS. Non-specific protein
binding sites were blocked by 1 hr incubation in a blocking buffer contain-
ing 1% non-fat milk in PBS. Cells were then incubated with anti-P-NFkB
(Abcam ab51059, Paris, France), anti-PKC zeta or anti-LEI/L-DNase II 1/
100, in 0.1% non-fat milk in PBS for 1 hr. This was followed by two
washes with PBS and incubation for 1 hr with a 1/500 dilution of anti-rab-
bit Alexa Fluor 546 conjugated antibody, or anti-rabbit Alexa Fluor 488
conjugated antibody, or anti-chicken Alexa Fluor 488 conjugated antibody
(Invitrogen, Life Technologies, Saint Aubin, France). Cells were then
washed twice with PBS, incubated for 1 min. with 4-6 di-aminidino-2-phe-
nyl indoledichloride (DAPI) 1/5000 (Sigma-Aldrich) and washed three
times with PBS. Finally, coverslips were mounted with fluoromount
(Sigma-Aldrich, Saint-Quentin Fallavier, France). Immunoreactivity was
visualized using fluorescence microscopy with an Olympus microscope
BX51 (Olympus France, Rungis, France).
ª 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
1647
J. Cell. Mol. Med. Vol 19, No 7, 2015
Western blot
After extraction of samples (retina or cells) with M-PER, protein mea-
surement was performed with bicinchoninic acid (BCA)TM Protein Assay
Kit (Thermo Scientific) using bovine serum albumin as standard. After
dilution of samples with Laemmli buffer, 25 lg of the extracted proteins
was separated by a 12% SDS-PAGE, immobilized on nitrocellulose
membrane (PROTAN, Whatman, GE Healthcare, Versailles, France)
and blotted with: anti-PKC zeta, anti-phospho-PKC zeta (Santa Cruz sc-
12894R; Santa Cruz Biotechnology), anti-PAR4 (Santa Cruz sc-1807;
Santa Cruz Biotechnology), anti-actin (Santa Cruz sc-1616; Santa Cruz
Biotechnology), anti-lamin B (Santa Cruz sc-6216; Santa Cruz Biotech-
nology) at 1/500 dilution or anti-LEI/L-DNase II at 1/1000 dilution. The
secondary antibodies conjugated to HRP (Vector, Eurobio, Les Ulis,
France) were used in a 1/5 000 dilution. Finally Luminata Forte Western
HRP Substrate (Millipore, Merck Chimie, Fontenay sous Bois, France)
was used to reveal the signal.
Site-directed mutagenesis
Site-directed mutagenesis was performed on wild-type (wt) LEI conju-
gated to pDsRed [12] using the Quick-Change mutagenesis kit from
Stratagene according to the manufacturer’s protocol. A threonine resi-
due located in position 195 was changed into a glutamate, and the
mutant was called T195E. Baby hamster kidney cells were seeded at a
density of 5 000 cells/cm2 on glass coverslips in 24-well plates. Two
hours before transfection, the culture medium was replaced with fresh
medium without foetal calf serum. The transfection medium contained
0.4 lg of pDsRed-T195E-LEI mutant, 0.4 lg of wt LEI coupled to GFP
[12] and 1 ll of Lipofectin reagent (Life Technologies, Inc., Saint Aubin,
France) per well. The transfection process occurred at 37°C for 5 hrs
and was stopped by adding the same volume of DMEM containing 20%
foetal calf serum. Coverslips were collected 24 hrs after transfection
and put in fresh medium containing or not 40 lM of HMA for 18 hrs.
Images were taken using a fluorescence microscopy.
Knockdown of PKC zeta by siRNA transfection
To perform knockdown experiments, HeLa cells were transfected with
50 nM of siRNA PKC zeta Smart pool (Thermo Scientific L-003526-00-
0005), or control siRNA (Santa Cruz sc-36869; Santa Cruz Biotechnol-
ogy) with AMAXA cell line nucleofector kit. Transfected cells were
seeded in four wells from a 24-well plate. After 17 hrs, cells were trea-
ted with TNFa and CHX, as before, for 7 hrs. Finally, a MTT (Thiazolyl
Blue Tetrazolium Bromide) reduction assay or a preparation of subcellu-
lar fractions was performed.
Viability assay based on MTT reduction
Thiazolyl Blue Tetrazolium Bromide (MTT) is a colorimetric assay based
on the ability of oxidoreductase enzymes to reduce the tetrazolium. In
our conditions, the MTT assay reflected cell viability. After 7 hrs of treat-
ment with TNFa/CHX, culture medium was removed and 250 ll of MTT
solution was added to each well (MTT from Sigma-Aldrich was diluted in
PBS at a concentration of 1 mg/ml). The plate was kept for 1 hr at 37°C.
Cells were then lysed with 250 ll of isopropanol. MTT reduction in each
sample was subsequently assessed by measuring absorption at 570 nm
versus 630 nm using a microplate reader (Bio-Rad, Marnes-la-Coquette,
France).
Preparation of subcellular fractions
For detection of LEI/L-DNase II redistribution after treatment, both the
cytosolic and the nuclear fractions were isolated from cells. 106 HeLa
cells were transfected (or not) with siRNA PKC zeta by AMAXA cell line
nucleofector then seeded in six well plates for 17 hrs. After treatment
with TNFa/CHX for 7 hrs, attached cells were collected by cell scrapping
using a rubber policeman, floating cells were collected by centrifugation
of the culture medium. Cells were pooled and washed two times in cold
PBS (every time at 370 9 g, 5 min. at 4°C). Cells were then collected
and resuspended in an ice-cold hypo-osmotic solution of 1.5 mM MgCl2.
After mechanical breakage of cell membranes by using a tight-fit Dounce
B potter (15 strokes) on ice, they were centrifuged and the cytoplasmic
fractions contained in the supernatants were collected. The pellets were
washed two times with the same MgCl2 solution and resuspended in
100 ll of m-PER extract reagent (Pierce). This was considered as the
nuclear fraction. Finally, the protein concentration in the cytoplasmic and
nuclear fractions, was performed with the BCA methodTM Protein Assay
Kit (Thermo Scientific). Bovine serum albumin was used as standard.
Laemmli buffer was added for further Western blot analysis.
Endonuclease activity assay
Retinal extracts (15 lg) were incubated at 37°C with 1.5 lg of pHook
plasmid in 20 mM Tris-EDTA buffer pH 5.5. 10 ll of the reaction was
sampled at different times. The samples were analysed on a 1% aga-
rose gel containing ethidium bromide (BET).
Results
Activation of PKC zeta in LIRD
To investigate the cellular mechanisms involved in retinal protection
during light exposure, we studied the status of PKC zeta. As other
PKCs, this kinase is mobilized to the cell membrane when activated.
So that, we analysed retinas from rats exposed to white light from dif-
ferent periods, by immunohistochemistry, using an anti-PKC zeta as
staining antibody (Fig. 1A). On day 1, we observed a staining of PKC
zeta in the outer and inner nuclear layers. On day 2, an intense label-
ling appeared at extensions of cells localized in the inner portion of
the retina (from the outer plexiform layer to the ganglion cell layer).
Although this staining of the extensions was still seen at 7 days of
exposure, the PKC zeta expression seemed to decrease after 7 days
of light exposure.
To verify if the change in PKC zeta localization after illumination
was because of an increase in protein expression, we analysed extracts
from whole retinas by Western blot (Fig. 1B). We observed that native
PKC zeta (72 kDa) increased from 1 to 5 days of light exposure com-
pared to retinas from rats kept in normal light conditions. After 9 days,
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expression of PKC zeta decreased to the control level. Different from
other experimental settings [21, 27], only a major band of 72 kDa was
observed in all conditions. No cleavage of PKC zeta was found.
Protein kinase C zeta is, in general, transiently activated. This acti-
vation is stopped by the release of the stress or by the induction of
cell death. If a caspase-dependent apoptosis pathway is activated,
PKC zeta is cleaved. As no fragment was found, we investigated if its
endogenous inhibitor, PAR-4 was synthesized. Figure 1C shows the
level of PAR-4 expression in neural retina after illumination. A weak
decrease in PAR-4 expression was seen at 1 and 2 days followed by
an important increase at 5 and 9 days. The late increase in PAR-4
expression together with the decrease in PKC zeta expression sug-
gested that this pathway was shutting down.
The interaction between LEI/L-DNase II and PKC
zeta
We have already shown that the caspase-independent pathway, LEI-
L-DNase II, is involved in photoreceptor cell death [9] during LIRD.
To investigate if PKC zeta was a possible modulator of this pathway
we investigated if this kinase could interact with LEI/L-DNase II. As
we presumed that this interaction, if it exists, could be a general
phenomenon not limited to the retina, we used cells in culture for
these experiments, to save as many rodents as possible. Routinely
we used both HeLa and BHK cells, which are cells from different spe-
cies (human and hamster respectively) and from different origin (epi-
thelial cancer cells and fibroblasts respectively), to avoid cell-specific
interactions. We first conducted pull-down experiments using a puri-
fied recombinant protein bearing an His-tag in its N-terminal end and
loaded on His-select cartridges. Figure 2A shows a Western blot of a
HeLa cell extract after elution from a LEI-loaded column, developed
with an anti-PKC zeta antibody. ‘Ctl’ represents the PKC zeta signal
obtained from 10 lg of total cell extract. ‘LEI’ indicates the material
obtained from elution of an LEI affinity column. A nickel resin charged
with an His-tagged calmodulin was used as the negative control.
Western blot revealed an intense PKC zeta band indicating that the
LEI/L-DNase II protein was able to bind PKC zeta in vitro.
To further confirm this interaction co-immunoprecipitations of
the proteins of interest were performed on BHK and HeLa cells
A
B C
Fig. 1 PKC zeta in retina during LIRD. (A)
Rats were exposed to a continuous white
light for 1–7 days, and then killed; eyes
were mounted in optimal cutting-tempera-
ture (OCT). Cryosections were stained
with anti-PKC zeta (green) and with propi-
dium iodide (DNA, red). Arrow head
shows translocation of PKC zeta to the
plasma membrane. ONL: outer nuclear
layer; INL: inner nuclear layer; GCL: gan-
glion cell layer. Scale bar represents
20 lm. (B) Western blot analysis of PKC
zeta expression at different times of light
exposure. Specificity of the antibody was
verified by competition with the specific
peptide (sc-216P). Lower panel shows the
quantification; means statistically different
with respect to control (P < 0.01 (ANOVA
test)) are indicated by an ‘*’. (C) same
experiment as in B using anti-PAR-4 anti-
body. Specificity of the antibody was veri-
fied by competition with the specific
peptide (sc-4216). ‘*’ indicates significant
differences with respect to the control, as
before. Actin was used as a charge con-
trol.
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extracts. Here again, different types of cells were used to avoid cell-
specific interactions. Western blot analysis revealed that PKC zeta
was co-immunoprecipitated with an anti-LEI antibody and that LEI
was co-immunoprecipitated with an anti-PKC zeta antibody. Any pro-
tein was detected by antibodies in the column loaded without IgG
(negative control) (Fig. 2B).
Taken together these results indicated that LEI and PKC zeta could
associate to each other.
The control of the LEI/L-DNase II pathway by
phosphorylation
To investigate if the LEI/L-DNase II pathway could be regulated by
PKC zeta, we looked for a putative PKC target sequence on LEI/L-
DNase II. In silico studies revealed the presence of a putative phos-
phorylation site near by the NLS of LEI. In fact, the threonine 195
located in the ‘linker’ sequence between the two lysine’s groups of
the NLS (Fig. 3A) corresponded to a consensus sequence of the PKC
phosphorylation substrate [28]. Using site-directed mutagenesis, we
substituted this threonine by a glutamate to mimic a constitutive
phosphorylation (the negative charge simulated the addition of a
phosphate group). The T195E mutation was made on a DsRed-LEI
chimera protein (red fluorescent protein). A GFP-LEI chimera (green
protein) was left unchanged and used as an internal control (wt LEI).
Next, BHK cells were cotransfected with these two proteins.
48 hrs after transfection, the cells were left untreated or induced in
apoptosis with 40 lM of HMA for 18 hrs. Subsequently, cells were
analysed by fluorescence microscopy (Fig. 3B). In control conditions,
the two proteins had the same cytoplasmic localization. However,
after induction of cell death by HMA, the T195E mutant, mimicking a
phosphorylation, was not translocated into the nucleus in contrast to
the wild type (WT) protein. These results suggested that the pseudo
threonine phosphorylation could control the nuclear translocation of
L-DNase II during apoptosis.
The effect of LEI-PKC zeta interaction on cell
survival in vitro
To estimate the functional impact of LEI/L-DNase II-PKC zeta interac-
tion on cell survival, we raised the hypothesis that under stress condi-
tions, PKC zeta was activated, resulting in the L-DNase II
phosphorylation. This phosphorylation could impair or slow down the
nuclear translocation of L-DNase II. In this way, the PKC zeta activa-
tion could exert its protective role.
As this issue was very difficult to study in the retina, we looked
for a cellular model of cell death where the activation of PKC zeta and
LEI/L-DNase II pathways were already described. We selected as a
model the treatment of HeLa cells with TNFa (50 ng/ml) and CHX
(10 lg/ml) for 7 hrs, a model described by Smith and Smith [29].
The activation of PKC zeta and LEI/L-DNase II in HeLa cells was
first evaluated by Western blot (Fig. 4A). The treatment with TNFa
plus CHX induced PKC zeta cleavage revealed by two new bands (at
approximately 50 and 40 kDa) with PKC zeta antibody. This proteo-
lytic degradation has been characterized as a cleavage of native PKC
zeta generating two catalytic domains and an increase in PKC zeta
activity [29]. We did not see an increase in phospho-PKC zeta protein
A
B
Fig. 2 Physical interaction between LEI/L-DNase II and PKC zeta. (A)
Pull down of PKC zeta using a LEI affinity column. An His-cartridge
resin was loaded with an His-tagged LEI. Crude extract of 100 lg from
HeLa cells was loaded on the column that was then washed and eluted.
The LEI line represents the material eluted from this column. As a nega-
tive control an his-tagged calmodulin was used as na€ıve protein. Ctl line
represents 10 lg of HeLa crude extract. (B) Crude extract of 100 lg
from HeLa cells was immunoprecipitated with anti-PKC zeta (PKC z line)
or anti-LEI (LEI line). A column without IgG was used as control (Ctl).
Western blots were developed with anti-PKC zeta (upper panel) or anti-
LEI (lower panel). These are representative experiments out of three.
A
B
Fig. 3 Putative phosphorylation site of LEI. (A) Fragment of the
sequence of LEI presenting the consensus site for PKC zeta. LEI from
several species are aligned showing that the sequence is well conserved
among species. (B) GFP-LEI (WT) was transfected to BHK cells together
with pDsRed-T195E-LEI (mutant protein). Cells were left untreated (Ctl
panel) or treated with HMA to induce apoptosis. Nuclear translocation
of the mutant protein is impaired. Scale bar represents 10 lm.
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(Fig. 4B) after treatment with TNFa/CHX. The activation of LEI/L-
DNase II pathway is revealed by an increase in L-DNase II band at
27 kDa in cells treated with TNFa plus CHX compared with control
cells (Fig. 4C). The activation of this apoptotic pathway has already
been described in a model of U937 cells treated with TNFa involving
protein AP24 (Apoptotic Protein) [30, 31].
To confirm the activation of both proteins, immunocytochemistry
was used to verify the subcellular localization of LEI/L-DNase II and
PKC zeta (Fig. 4D). In normal cells, LEI and PKC zeta had a cytoplas-
mic localization. In cells treated with TNFa/CHX, we have a nuclear
translocation of both proteins. To further confirm the PKC zeta activa-
tion, we investigated the status of phospho-NFkB (active form of
NFkB pathway) as this transcription factor is one of the substrates of
PKC zeta [22, 32]. We observed an increase in nuclear staining of






Fig. 4 L-DNase II control by PKC zeta in HeLa cells. HeLa cells were induced in apoptosis by TNFa/cycloheximide. (A) Western blot analysis of PKC
zeta in total extract of HeLa cells treated with TNFa/CHX (TNF) or left untreated (Ctl). Arrow heads indicate the fragments of PKC zeta. (B) Western
blot analysis of serine 311 phosphorylated PKC zeta in TNFa/CHX treated or untreated cells (Ctl) The specificity of the antibody was performed by
digesting the protein extract with 1 IU of calf intestinal alkaline phosphatase, invitrogen 18009-019. (C) Western blot analysis of LEI/L-DNase II in
total extract of HeLa cells treated with TNFa/CHX (TNF) or left untreated (Ctl). Arrow head indicates L-DNase II. (D) Immunocytochemistry analysis
of LEI/L-DNase II (green), PKC zeta (red) and NFkB (green) activation. Nuclei were counterstained with DAPI (blue). Arrow heads indicate intensely
stained nuclei. Scale bar represents 10 lm. (E) HeLa cells were transfected with a siRNA against PKC zeta (siRNA) or with a control siRNA (Ctl).
The decrease in PKC expression was controlled by Western blot (data not shown). After induction of apoptosis by TNFa/CHX treatment, the rate of
cell death was evaluated using the MTT method. The means are significantly different P < 0.05, as determined by the test (*). (F) Same experiment
as in E but nuclear and cytoplasmic fractions were performed and studied by Western blot for LEI/L-DNase II expression. The presented results cor-
respond to cells transfected with a siRNA against PKC zeta (+) or a control siRNA (). Arrow head indicates L-DNase II.
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Taken together these results confirmed that LEI/L-DNase II and
PKC zeta pathways were activated in HeLa cells treated with TNFa/
CHX.
After validation of the cellular model, we investigated the effect of
LEI-PKC zeta interaction on cell survival. We performed PKC zeta spe-
cific knockdown assays using siRNA transfection in HeLa cells before
treatment with TNFa/CHX. Then we used the MTT assay to estimate
the cell viability. As seen in Figure 4E, the rate of cell death was
increased in PKC zeta siRNA-transfected and treated cells compared
with cells transfected with a control siRNA. This result suggests that
PKC zeta knockdown had an effect on cell death induced in these con-
ditions of apoptosis.
To verify if this increased cell death is linked to an increase in
death induced by the LEI/L-DNase II pathway we performed a
nuclear/cytoplasmic fractionation of HeLa cells treated or not with
TNFa/CHX for 7 hrs after the PKC zeta knockdown (Fig. 4F). In
nuclear fractions of TNFa/CHX-treated cells, we confirmed the
presence of L-DNase II at 27 kDa, not seen in control (not treated
with TNFa/CHX) cells. The PKC zeta knockdown in treated cells
induced an increase in nuclear translocation of L-DNase II com-
pared to cells expressing a regular amount of PKC zeta. These
results suggested that in this apoptotic condition, the PKC zeta
partially impairs the activity of the LEI/L-DNase II pathway by
retaining some of the L-DNase II already produced at the cyto-
plasm.
Taken together all these results suggested that the LEI-PKC zeta
interaction had a functional impact on cell survival and that PKC zeta
was able to regulate apoptosis induced by LEI/L-DNase II by decreas-
ing its nuclear translocation during apoptosis.
The effect of PKC inhibition on L-DNase II
activity in vivo
The results obtained above suggested a protective role of PKC zeta
against LEI/L-DNase II-induced apoptosis in a cellular model very dif-
ferent from our original concern. Next step was then to investigate if
they were transposable to LIRD. To investigate this issue we injected
intravitreally a pharmacological PKC zeta specific inhibitor before light
exposure. Then we measured the endonuclease activity of retina total
extracts by comparing the injected rats to control rats injected only
with the vehicle solution. The endonuclease activity was measured by
analysing, on an agarose gel, the degradation rate of a supercoiled
plasmid (pHook). Figure 5A shows the obtained results. We found an
increase in the degradation of the plasmid in the extracts treated with
the inhibitor compared to those treated with the vehicle. In retinas
from eyes treated with the vehicle solution we saw a progressive but
weak increase in L-DNase II activity as time of exposure increased
(the lower molecular weight band appeared at 30 min. after 1 day of
exposure, 20 after 2 days and 10 for the 5th day). In every case the
intravitreal injection on the PKC inhibitor increased this activity.
To confirm this PKC zeta inhibitor effect on LEI/L-DNase II path-
way, we investigated the protein pattern of LEI in the retina after injec-
tion and light exposure (Fig. 5B). At 2 days, Western blot analysis
revealed an increase in L-DNase II bands at 42 kDa and at 27 kDa in
retina treated with PKC zeta inhibitor compared to retina injected with
the vehicle. The intravitreal injection of PKC zeta inhibitor had no
impact on the LEI/L-DNase II protein expression in retina non-
exposed to light (Ctl) (no difference between non-exposed injected
with inhibitor or with vehicle).
A
B
Fig. 5 L-DNase II expression and activity
in light-exposed rat retinas. (A) Rats were
exposed to continuous white light for
2 days (2d) or kept in a normal, cycling
light (Ctl). Previous to illumination the
inhibitor of PKC zeta was intravitreally
injected in the right eye. The left eye was
injected with the vehicle. After killing, the
retinas were dissected, extracted and anal-
ysed for L-DNase II activity using a super-
coiled plasmid in ionic DNase II activating
conditions. The right panel is a quantifica-
tion of the lower band (product of degra-
dation). This is a representative
experiment out of three. (B) Same experi-
ment as in A but in this case LEI/L-DNase
II was analysed by Western blot right
panel represent a representative experi-
ment out of four. Right panel represents
the quantification of the L-DNase II band;
P < 0.05 (*).
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Taken together all these results suggested that the PKC zeta inhi-
bition promoted the LEI/L-DNase II pathway by an increase in its
endonuclease activity and its nuclear translocation (27 kDa band).
Discussion
In this study we investigated, for the first time, the putative regulation
of LEI/L-DNase II by a kinase involved in a cell survival pathway, the
atypical PKC zeta, in a LIRD model. We show that LEI/L-DNase II,
effector of cell death in this model, can interact with PKC zeta, and
that inhibition of PKC zeta can modulate the pro-apoptotic activity of
L-DNase II probably by impairing its nuclear translocation.
We have previously shown that in LIRD photoreceptor cell death
is mediated by a caspase-independent pathway [9, 10]. It seems then
interesting to use this knowledge to control and, eventually, slow
down degeneration. To get some inside in the regulation of the activ-
ity of L-DNase II we investigated its possible interactions in a high
output screening. The results obtained drove our attention to PKC
zeta, a kinase already identified as possible protection kinase in
NMDA-induced stress [21, 27]. As it was the case for NMDA, PKC
zeta was also activated in LIRD. Moreover, as for NMDA stress, this
activation could be transiently, although this is not as clear as in the
NMDA model.
In NMDA-treated eyes a cleavage of PKC zeta seems responsible
for the shutdown of its protective effect [27]. Actually, the cleavage
of PKC zeta leads to a constitutive activation, to its nuclear translo-
cation and to the induction of apoptosis [27]. In LIRD this cleavage
was not found, but the increase in its specific inhibitor, PAR-4, may
be inactivating the enzyme; leading by a different mechanism to the
decrease in its protective effect. The PKC zeta/PAR-4 association is
described in many studies where it is shown that the interaction of
these two proteins leads to inactivation of the PKC zeta survival
pathway through inhibition of the NFkB pathway [33]. In our LIRD
model, these results suggest that in the early days of illumination,
low PAR-4 level allows to maintain the survival pathway in light
exposed retinas. However, after 5 days of continuous light exposure,
the PAR-4 level increases which allow its interaction with activated
PKC zeta resulting in the inhibition of survival pathway and induction
of apoptosis. These assumptions were not verified in this model,
because it was not our main concern but they are in accord with the
existing literature.
Pull-down and co-immunoprecipitation studies indicate that both
molecules can interact. In silico studies identify a consensus phos-
phorylation site for LEI/L-DNase II and the mutagenesis of this site,
mimicking a phosphorylation, impairs its nuclear translocation. More
importantly, when PKC zeta is inhibited by siRNA in a cell model of
LEI activation, L-DNase II increases in the nucleus and the survival of
these cells is decreased. Although these results were obtained in a
cellular model, the increase in L-DNase II expression and activity in
light exposed retinas treated with a PKC inhibitor seem to validate, or
at least to support the idea that the same process is occurring in the
retina. The studies presented here do not permit to say if this interac-
tion is direct or mediated though other molecules, whether these are
kinases or not. Further investigation using recombinant molecules in
vitro should allow to precise this point.
The activation of some kinases during LIRD has already been
described. This is the case for the Ceramide kinase such as[34],
phosphoinositide 3 Kinase (PI3 kinase) [35], AKT [36]. The data pre-
sented in this study show, for the first time, the involvement and acti-
vation of PKC zeta in LIRD, adding this protective pathways to other
kinases already described as protective in this context. We also show
that PKC zeta is able to regulate the LEI/L-DNase II pathway, which is
a caspase-independent cell death pathway, so that extending to these
type of pathways a property already shown for caspase-dependent
apoptosis [21, 37]. Finally, we show that the LEI/L-DNase II pathway
could possibly be regulated by phosphorylation, adding new light in
the regulation of this pathway, already shown as regulated by non-
caspases proteases [9, 30, 38, 39].
This study gives new insight on retinal degeneration, an
important issue in the understanding of photoreceptor demise. All
together, the data we reported indicate that the events produced
in photoreceptors may fit to the model displayed on Figure 6.
According to this model the intracellular increase in Ca2+ concen-
tration induced by light [5] activates calpains that permeabilize the
lysosomal membrane by cleaving the lysosomal associated mem-
brane protein 2 [39]. This permeabilization releases, among other
proteases, cathepsin D [9]. Cathepsin D activates L-DNase II that
translocates to the nucleus to cleave DNA and to induce photore-
ceptor cell death [9]. The nuclear translocation of L-DNase II may
be inhibited by PKC zeta by phosphorylation. However, PKC zeta
is also an activator of the NFkB pathway, known to have a role in
Fig. 6 Schematic model of PKC zeta and LEI/L-DNase II in LIRD. Light
induces intracellular increase in Ca2+ concentration that activates cal-
pains. In turn, calpain 1 permeabilizes the lysosomal membrane. This
releases cathepsin D that activates L-DNase II which is translocated to
the nucleus to induce photoreceptor cell death. This nuclear transloca-
tion is inhibited by PKC zeta to protect the cell. PKC zeta can also acti-
vate other anti-apoptotic proteins. Its protective action can be inhibited
by its specific inhibitor PAR-4 (*).
ª 2015 The Authors.
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modulating apoptosis through the synthesis of anti-apoptotic fac-
tors, an issue that we have not evaluated in this work. Moreover,
it has been shown that PKC zeta interacts with p62 (sequesto-
some) [40] and with the receptor interacting protein kinase [41].
These data place PKC zeta at the interface of apoptosis (caspase
dependent and independent), oxidative stress response and necro-
sis, becoming the master of the cell signalling orchestra. In addi-
tion, PKC zeta by interacting with PAR-6 (partitioning-defective
protein) and the tight junction protein ZO-1 regulates the assembly
of tight junctions [42], a structure that can also be modified in
LIRD.
In conclusion, we have shown that PKC zeta is activated in LIRD.
This activation regulates L-DNase II an apoptosis effector in this
degenerative model. Further work is needed to fully characterize the
protective effect of this kinase in retinal degenerations.
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